Cargando...
Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms
PURPOSE: Immune checkpoint inhibitors have recently been approved by the US FDA as first and/or second line therapy in a subset of cancer types. Recent evidence suggests that the quantity of tumor infiltrating lymphocytes (TILs) influences the likelihood of response to immune checkpoint inhibitors....
Guardado en:
| Publicado en: | Cell Oncol (Dordr) |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Netherlands
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214387/ https://ncbi.nlm.nih.gov/pubmed/32141029 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-020-00496-7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|